These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 6384701)

  • 1. [Squaric acid dibutyl ester in the treatment of severe alopecia areata].
    Miranda A; Mato F; Quiñones PA
    Med Cutan Ibero Lat Am; 1984; 12(3):273-8. PubMed ID: 6384701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normalisation of hair follicle morphology in C3H/HeJ alopecia areata mice after treatment with squaric acid dibutylester.
    Gardner S; Freyschmidt-Paul P; Hoffmann R; Sundberg JP; Happle R; Lindsey NJ; Tobin DJ
    Eur J Dermatol; 2000 Aug; 10(6):443-50. PubMed ID: 10980465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired-comparison, clinical trial.
    Dall'oglio F; Nasca MR; Musumeci ML; La Torre G; Ricciardi G; Potenza C; Micali G
    J Dermatolog Treat; 2005 Feb; 16(1):10-4. PubMed ID: 15897160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the topical sensitizer squaric acid dibutyl ester in Alopecia areata and factors influencing the outcome.
    Ajith C; Gupta S; Kanwar AJ
    J Drugs Dermatol; 2006 Mar; 5(3):262-6. PubMed ID: 16573260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of alopecia areata with squaric acid dibutylester.
    Hill ND; Bunata K; Hebert AA
    Clin Dermatol; 2015; 33(3):300-4. PubMed ID: 25889130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of alopecia areata with squaric acid dibutylester.
    Caserio RJ
    Arch Dermatol; 1987 Aug; 123(8):1036-41. PubMed ID: 3307636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Topical therapy of alopecia areata with squaric acid dibutyl ester].
    Morishita M; Nagai T; Sato Y
    Nihon Hifuka Gakkai Zasshi; 1987 Jan; 97(1):61-4. PubMed ID: 3573366
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of severe alopecia areata with squaric acid dibutylester in pediatric patients.
    Orecchia G; Malagoli P; Santagostino L
    Pediatr Dermatol; 1994 Mar; 11(1):65-8. PubMed ID: 8170854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical immunotherapy of alopecia areata. A follow-up study.
    Valsecchi R; Cainelli T; Foiadelli L; Rossi A
    Acta Derm Venereol; 1986; 66(3):269-72. PubMed ID: 2426909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of topical sensitizers in the treatment of alopecia areata.
    Rokhsar CK; Shupack JL; Vafai JJ; Washenik K
    J Am Acad Dermatol; 1998 Nov; 39(5 Pt 1):751-61. PubMed ID: 9810892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of alopecia areata with topical sensitizers.
    Sutherland L; Laschinger M; Syed ZU; Gaspari A
    Dermatitis; 2015; 26(1):26-31. PubMed ID: 25581667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diphencyprone in the treatment of alopecia areata.
    Happle R; Hausen BM; Wiesner-Menzel L
    Acta Derm Venereol; 1983; 63(1):49-52. PubMed ID: 6191489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fexofenadine hydrochloride enhances the efficacy of contact immunotherapy for extensive alopecia areata: Retrospective analysis of 121 cases.
    Inui S; Nakajima T; Toda N; Itami S
    J Dermatol; 2009 Jun; 36(6):323-7. PubMed ID: 19500180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [DNCB therapy of alopecia areata].
    Happle R
    Z Hautkr; 1979 May; 54(10):426-9. PubMed ID: 314203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged dermatitis distant to the site of squaric acid dibutyl ester applications and recovery of alopecia areata.
    Ujiie H; Sawamura D; Shibaki A; Shimizu H
    Clin Exp Dermatol; 2005 Sep; 30(5):579-80. PubMed ID: 16045698
    [No Abstract]   [Full Text] [Related]  

  • 16. Discoid lupus erythematosus exacerbated by contact dermatitis caused by use of squaric acid dibutylester for topical immunotherapy in a patient with alopecia areata.
    Shimaoka Y; Hatamochi A; Hamasaki Y; Suzuki H; Ikeda H; Yamazaki S
    J Dermatol; 2008 Mar; 35(3):151-3. PubMed ID: 18346258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pigmentation abnormalities in the course of topical immunotherapy of alopecia areata].
    Valsecchi R; Pansera B; Rossi A; Cainelli T
    G Ital Dermatol Venereol; 1989; 124(1-2):31-2. PubMed ID: 2527809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of alopecia areata-like hair loss with the contact sensitizer squaric acid dibutylester (SADBE) in C3H/HeJ mice.
    Freyschmidt-Paul P; Sundberg JP; Happle R; McElwee KJ; Metz S; Boggess D; Hoffmann R
    J Invest Dermatol; 1999 Jul; 113(1):61-8. PubMed ID: 10417620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical immunotherapy with squaric acid dibutylester: unusual hair pigmentary changes in two cases of alopecia areata.
    Mastrolonardo M; Diaferio A
    J Eur Acad Dermatol Venereol; 2002 Mar; 16(2):186. PubMed ID: 12046838
    [No Abstract]   [Full Text] [Related]  

  • 20. [In situ lymphocyte subpopulation in alopecia areata after treatment with squaric acid dibutyl ester].
    Rosso R; Paulli M; Marelli MA; Douville H; Orecchia G
    G Ital Dermatol Venereol; 1988 Nov; 123(11):575-7. PubMed ID: 3254332
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.